All In Biotech

Drug Trial Radar · NCT07174687

SGLT2 Inhibitors in Geographic Atrophy

Efficacy of Dapagliflozin in the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Dec 2, 2025

Primary completion

Dec 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and evidence of activity of SGLT2 inhibitors in subjects with Geographic Atrophy associated with AMD.

Conditions

  • Retinal Degeneration
  • Retinal Diseases
  • Eye Diseases
  • Geographic Atrophy
  • Pathological Conditions, Anatomical

Interventions

  • DapagliflozinDrug

    Dapagliflozin is an SGLT2 inhibitor used in diabetes, heart failure, and chronic kidney disease patients.

  • Matching PlaceboOther

    Matching oral placebo to dapagliflozin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12Time frame: Baseline (screening) and Month 12.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.